ArticleNeurocritical care2026
Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) Study: Study Protocol for a Prospective, Multicenter, Randomized Trial.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RHOA at the intersection of inflammation-driven and sporadic colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating condition, with cerebral vasospasm and subsequent delayed cerebral ischemia being key contributors to poor neurological outcomes. In Japan, fasudil is the standard prophylactic agent used to mitigate vasospasm, though its efficacy in improving long-term functional outcomes remains uncertain. Clazosentan, a selective endothelin-A receptor antagonist, has demonstrated potential in reducing vasospasm-related morbidity in phase 3 trials. However, no randomized controlled trial directly comparing the effects of fasudil and clazosentan on functional independence exists in Japan. The primary objective of this study is to determine the superiority of clazosentan over fasudil in enhancing functional outcomes among patients with aSAH. The Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) study is a multicenter, randomized, open-label, parallel-group superiority trial conducted across 21 high-volume stroke centers. Patients with aSAH secured within 48 h of onset will be randomized in a 1:1 ratio to receive either intravenous clazosentan or fasudil. The primary outcome is the proportion of patients achieving a favorable functional outcome (modified Rankin Scale 0-2 at 90 days post-onset). Secondary outcomes include modified Rankin Scale (mRS) score at discharge, incidence of cerebral vasospasm and vasospasm-related delayed cerebral ischemia, and safety profiles, with particular attention to fluid retention-related complications. This trial is the first to directly compare the efficacy and safety of clazosentan vs. fasudil. By selecting the local standard of care as the comparator, the study is designed to generate pragmatic, high-impact evidence that can inform clinical decision-making and potentially reshape treatment guidelines for aSAH management in Japan. It will provide the first high-quality data from a direct comparison of clazosentan and fasudil, in a nimodipine-free population-a clinical question not addressed by previous international trials.
Indexed as
Identifiers
41927991What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.